| Literature DB >> 19609398 |
Ibrahim A Darwish1, Sawsan M Amer, Heba H Abdine, Lama I Al-Rayes.
Abstract
New simple spectrofluorimetric method with enhanced sensitivity has been developed and validated for the determination of the antidepressant paroxetine (PXT) in its dosage forms and plasma. The method was based on nucleophilic substitution reaction of PXT with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole in an alkaline medium (pH 8) to form a highly fluorescent derivative that was measured at 545 nm after excitation at 490 nm. The factors affecting the reaction was carefully studied and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was presented. Under the optimized conditions, linear relationship with good correlation coefficient (0.9993) was found between the fluorescence intensity and PXT concentration in the range of 80-800 ng ml(-1). The limits of detection and quantitation for the method were 25 and 77 ng ml(-1), respectively. The precision of the method was satisfactory; the values of relative standard deviations did not exceed 3%. The proposed method was successfully applied to the determination of PXT in its pharmaceutical tablets with good accuracy; the recovery values were 100.2 +/- 1.61%. The results obtained by the proposed method were comparable with those obtained by the official method. The proposed method is superior to the previously reported spectrofluorimetric method for determination of PXT in terms of its higher sensitivity and wider linear range. The high sensitivity of the method allowed its successful application to the analysis of PXT in spiked human plasma. The proposed method is practical and valuable for its routine application in quality control and clinical laboratories for analysis of PXT.Entities:
Keywords: NBD-C; paroxetine; pharmaceutical analysis; spectroflourimetry
Year: 2008 PMID: 19609398 PMCID: PMC2701171 DOI: 10.4137/aci.s1053
Source DB: PubMed Journal: Anal Chem Insights ISSN: 1177-3901
Figure 1Excitation (1) and emission (2) spectra of the reaction product of PXT (300 ng ml−1) with NBD-Cl (0.2%, w/v).
Figure 2Effect of NBD-Cl concentration (•) and pH (◆) on the fluorescence intensity of the product of the reaction of PXT (600 ng ml −1) and NBD-Cl.
Figure 3Effect of time on the reaction of NBD-Cl (0.2%, w/v) with PXT (600 ng ml−1) at different temperatures. RFI is the relative fluorescence intensity.
Optimization of variables affecting the reaction of PXT with NBD-Cl.
| NBD-Cl (%, w/v) | 0.01–0.5 | 0.2 |
| pH | 5–9.5 | 8 ± 0.2 |
| Temperature (°C) | 25–70 | 40 |
| Time (min) | 5–60 | 30 |
| HCl (M) | 0.02–0.5 | 0.1 |
| Solvent | Different | Acetone |
| Stability of PXT-NBD (min) | 10–60 | 60 |
aSolvents tested: methanol, ethanol, isopropanol, acetone, and acetonitrile.
bThe stability of the PXT-NBD was studied after dilution of the reaction solution.
Figure 4Scheme for the reaction pathway of PXT with NBD-Cl.
Figure 5Arrhenius plot for the reaction of NBD-Cl and PXT. T and K are the absolute temperature and the apparent rate constant, respectively. [PXT] is 8.2 × 10−7 M and [NBD-Cl] is 1 × 10−3 M.
Figure 6Calibration curve for spectrofluorimetric determination of PXT based on its reaction with NBD-Cl reagent. RFI is the relative fluorescence intensity.
Statistical parameters for the determination of PXT by the proposed spectrofluorimetric method based on its reaction with NBD-Cl.
| λex (nm) | 490 |
| λem (nm) | 545 |
| Linear range (ng ml−1) | 80–800 |
| Intercept | 5.3550 |
| SD of intercept | 1.7646 |
| Slope | 0.2304 |
| SD of slope | 0.0037 |
| Correlation coefficient (r) | 0.9993 |
| LOD (ng ml−1) | 25 |
| LOQ (ng ml−1) | 77 |
Recovery studies for determination of PXT by the proposed spectrofluorimetric method based on its reaction with NBD-Cl.
| 100 | 100.2 ± 1.05 |
| 150 | 97.8 ± 1.85 |
| 200 | 99.4 ± 1.28 |
| 250 | 98.4 ± 1.04 |
| 300 | 101.2 ± 1.34 |
aValues are mean of three determinations.
Analysis of PXT in presence of common excipients by the proposed spectrofluorimetric method.
| Starch (50) | 102.36 ± 1.82 |
| Glucose (10) | 98.76 ± 1.59 |
| Lactose (10) | 99.52 ± 2.04 |
| Acacia (10) | 101.49 ± 2.15 |
| Talc (5) | 103.02 ± 1.95 |
| MS | 99.01 ± 1.76 |
| Average ± SD | 100.69 ± 1.83 |
aValues are mean of three determinations.
bFigures in parenthesis are the amounts in mg added per 50 mg of PXT.
cMS = Magnesium stearate.
Analysis of PXT-containing-tablets by the proposed and the official methods.
| Seroxate tablets | 100.2 ± 1.61 | 99.6 ± 1.22 | 2.63 | 1.74 |
aValues are mean of 5 determinations.
bReference 6.
cThe tabulated values of t- and F- at 95% confidence limit are 2.78 and 6.39, respectively
Analysis of PXT spiked in plasma samples by the proposed spectrofluorimetric method.
| 30 | 29.4 | 98.0 ± 2.85 |
| 80 | 77.9 | 97.4 ± 2.41 |
| 120 | 117.0 | 97.5 ± 1.85 |
| 240 | 245.2 | 102.2 ± 2.97 |
| 500 | 490.5 | 98.1 ± 1.56 |